JOIN US FOR
2024 PEDS
A VIRTUAL CONFERENCE | OCT. 9-10, 2024
Reality Check: Entrepreneurship and Regulatory Navigation in Pediatric Cancer Drug Development
PEDS Co-Chairs
Brenda Weigel, MD
Director, Division of Pediatric Hematology/Oncology
University of Minnesota’s Masonic Cancer Center
CureSearch Scientific Advisory Council Chair
Jeffrey Skolnik, MD
Vice President, Clinical Development
Inovio Pharmaceuticals Inc.
CureSearch Industry Advisory Council Chair
WHAT ARE PEOPLE SAYING ABOUT PEDS?
"There are lots of moving parts to PIPs/PSPs but with the right knowledge and support, that can be done in a way that supports drug development in pediatric oncology."
“The pediatric oncology community (academia, industry, regulatory, advocacy) is made up of a very special set of dedicated experts working diligently to improve pediatric drug development.”
“There are many people working very hard to figure out how to advance drugs for children. On the other hand, companies aren't really geared up for the process yet.”
“This was truly a one-of-a-kind effort that's invaluable to our community!”
“Collaboration/partnership/Communication. It's not anything revelatory, but the sessions reinforced the importance of these concepts across all of Peds Oncology development. The better and more efficient that industry, regulators and academia can be at working together, the faster that new and better drugs will become available for pediatric cancer patients.”
“I really wanted to thank the organizers for allowing for enough time for substantive discussions. The Q&A sessions were brilliant.”
FULL AGENDA - COMING SOON
Subject to change*
PEDS day 1 | Wednesday, October 9th, 2024
OPENING REMARKS
Event begins at 10:00 AM EST
Led by Co-Chairs: Brenda Weigel, MD and Jeffrey Skolnik, MD
Welcome to 2024 PEDS
Intro to CureSearch
Brief highlights of current YI, AI, and Catapult awardees
SESSION 1: REGULATORY LANDSCAPE
Session begins at 10:30 AM EST
Featured speaker: Nicole Drezner, MD, Deputy Director, Division of Oncology 2 at FDA
Charting the Evolving Regulatory Landscape in Pediatric Oncology Drug Development
Key Topics:
Status of PRVs/Creating Hope Act Reauthorization
FDA accelerated approval
Project Optimus
Real-word evidence
Pediatric oncology drugs developed in the past year
BREAK FOR LUNCH
12:30 to 1:15 PM EST
SESSION 2: FINANCE AND INVESTMENT LANDSCAPE
Session begins at 10:30 AM EST
Featured speaker: Samuel Blackman, MD, PhD, Co-Founder and Head of Research and Development at Day One Biopharmaceuticals
“If You Build It, Will They Come?” – How Can We Build the Case for Investing in Pediatric Oncology Drug Development?
Key Topics:
Changes in biotech investment landscape in the last 2 years
Inflation Reduction Act
Impact on rare disease/peds oncology investments
Outlook moving forward
DAY 1 CLOSING REMARKS
3:15 to 3:30 PM EST
Led by Co-Chairs: Brenda Weigel, MD and Jeffrey Skolnik, MD
PEDS day 2 | Thursday, October 10th, 2024
DAY 2 OPENING REMARKS
Begins at 10:00 AM EST
Led by Co-Chairs: Brenda Weigel, MD and Jeffrey Skolnik, MD
SESSION 3: NEW COMPANIES AND ACADEMIC SPIN-OFFS
Session begins at 10:15 AM EST
Featured speaker: David Largaespada, PhD, Chairman and Founder of Luminary Therapeutics
From Bench to Boardroom: The Journey of Academic Innovators in Pediatric Oncology Drug Development
Key Topics:
The creation of new pediatric oncology-focused companies: What has worked and what hasn't?
What happens when vision meets reality?
What should we be doing differently?
BREAK FOR LUNCH
12:30 to 1:00 PM EST
SESSION 4: PUBLIC/PRIVATE PARTNERSHIPS AND BIG TRIAL IDEAS
Session begins at 1:00 PM EST
Featured speakers:
Chaired by Peter Adamson, MD, PhD, Global Head, Senior Vice President, Oncology Development & Pediatric Innovation, Sanofi
Panelist: Stacey Adam, PhD, Director of Cancer Research Partnerships at Foundation for the National Institutes of Health (FNIH)
Partnering for Progress: Strategies for Engaging Investors in Pediatric Oncology Public-Private Partnerships
What has worked and what hasn’t? How can we support increased investment in these efforts?
DAY 2 CLOSING REMARKS
3:15 to 3:30 PM EST
Led by Co-Chairs: Brenda Weigel, MD and Jeffrey Skolnik, MD